Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17307151 | 0.71 | CA2 (0.38) | ALDH1A1TSHRCA2 | |
| SCHEMBL10453055 | 0.68 | CA2 (0.44) | ALDH1A1LMNAGAATSHRCA2 | |
| SCHEMBL10523675 | 0.64 | CA2 (0.60) | ALDH1A1LMNATSHRCA2KDM4E | |
| SCHEMBL8310680 | 0.63 | CYP2C19 (0.46) | ALDH1A1LMNAGAATSHRKDM4E | |
| SCHEMBL26652074 | 0.62 | GABRA1 (0.47) | ALDH1A1LMNAGAATSHRCA2 | |
| SCHEMBL11954931 | 0.62 | CA2 (0.39) | ALDH1A1LMNAGAATSHRCA2 | |
| SCHEMBL22380057 | 0.61 | ALDH1A1 (0.43) | ALDH1A1LMNAGAATSHRCA2 | |
| SCHEMBL17616520 | 0.61 | CA2 (0.38) | ALDH1A1TSHRCA2 | |
| SCHEMBL11955172 | 0.60 | MAOA (0.44) | ALDH1A1TSHRCA2 | |
| SCHEMBL5350489 | 0.59 | MAOA (0.42) | ALDH1A1LMNATSHRCA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9394257-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | ALDH1A1 2333/4885LMNA 1822/4885GAA 2655/4885 |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | ALDH1A1 2333/4885LMNA 1822/4885GAA 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.